ARTICLE | Company News
Accentia, Baxter deal
December 6, 2010 8:00 AM UTC
Accentia received exclusive, worldwide rights to purchase Baxter's Cytoxan cyclophosphamide, which is marketed for cancer indications. Accentia will use the supply to manufacture its Revimmune cyclo...